Interestingly, in the MCI and AD groups, the classification outputs are significantly associated with clinical measures, such as apolipoprotein E genotype, polygenic risk scores, polygenic hazard scores, cerebrospinal fluid Aβ, and Tau, cognitive ability score, the conversion time for progressive MCI subjects and cognitive changes, thus, highlighting the solid biological/clinical basis underlying the progression of AD (9). The gene discussed is MAPT; the disease is Alzheimer disease.